Malignant haemangioendothelioma of bone in a HbSC disease patient--a case report.
Identifieur interne : 000159 ( Ncbi/Merge ); précédent : 000158; suivant : 000160Malignant haemangioendothelioma of bone in a HbSC disease patient--a case report.
Auteurs : W A Shokunbi [Nigeria] ; O B Campbell ; J O OgunbiyiSource :
- African journal of medicine and medical sciences [ 0309-3913 ] ; 1996.
Descripteurs français
- KwdFr :
- Adulte, Association thérapeutique, Biopsie, Drépanocytose (), Humains, Hémangioendothéliome (diagnostic), Hémangioendothéliome (radiothérapie), Hémangioendothéliome (secondaire), Hémangioendothéliome (traitement médicamenteux), Ilium, Issue fatale, Jambe, Mâle, Tumeurs des tissus mous (diagnostic), Tumeurs des tissus mous (radiothérapie), Tumeurs des tissus mous (secondaire), Tumeurs des tissus mous (traitement médicamenteux), Tumeurs osseuses (), Tumeurs osseuses (anatomopathologie), Tumeurs osseuses (radiothérapie), Tumeurs osseuses (traitement médicamenteux).
- MESH :
- anatomopathologie : Tumeurs osseuses.
- diagnostic : Hémangioendothéliome, Tumeurs des tissus mous.
- radiothérapie : Hémangioendothéliome, Tumeurs des tissus mous, Tumeurs osseuses.
- secondaire : Hémangioendothéliome, Tumeurs des tissus mous.
- traitement médicamenteux : Hémangioendothéliome, Tumeurs des tissus mous, Tumeurs osseuses.
- Adulte, Association thérapeutique, Biopsie, Drépanocytose, Humains, Ilium, Issue fatale, Jambe, Mâle, Tumeurs osseuses.
English descriptors
- KwdEn :
- Adult, Anemia, Sickle Cell (complications), Biopsy, Bone Neoplasms (complications), Bone Neoplasms (drug therapy), Bone Neoplasms (pathology), Bone Neoplasms (radiotherapy), Combined Modality Therapy, Fatal Outcome, Hemangioendothelioma (diagnosis), Hemangioendothelioma (drug therapy), Hemangioendothelioma (radiotherapy), Hemangioendothelioma (secondary), Humans, Ilium, Leg, Male, Soft Tissue Neoplasms (diagnosis), Soft Tissue Neoplasms (drug therapy), Soft Tissue Neoplasms (radiotherapy), Soft Tissue Neoplasms (secondary).
- MESH :
- complications : Anemia, Sickle Cell, Bone Neoplasms.
- diagnosis : Hemangioendothelioma, Soft Tissue Neoplasms.
- drug therapy : Bone Neoplasms, Hemangioendothelioma, Soft Tissue Neoplasms.
- pathology : Bone Neoplasms.
- radiotherapy : Bone Neoplasms, Hemangioendothelioma, Soft Tissue Neoplasms.
- secondary : Hemangioendothelioma, Soft Tissue Neoplasms.
- Adult, Biopsy, Combined Modality Therapy, Fatal Outcome, Humans, Ilium, Leg, Male.
Abstract
We report here a 35-year-old man with sickle cell disease (SCD), who presented in 1989 with pain in the (R) hip of 7 years duration and swelling of the (R) calf of 3 months duration. Clinical examination revealed a hard tender mass in the (R) calf. Histology of the (R) calf mass revealed haemangioendothelioma (HE), similar to the histology of the (R) iliac bone mass obtained in another institution previously. He was treated with external radiotherapy with the 1.25 megavoltage beam to antero-posterior fields of the (R) hemipelvis and (R) calf, with good response. Chemotherapy was subsequently administered using 6 cycles of VAC regime. The patient remained in remission for 12 months. In 1991 he had lymphoedema of (R) lower limb and received further radiotherapy and chemotherapy after an isotope bone scan had revealed disease activity in the (R) hemipelvis, (R) femur and (L) upper tibia. He responded again with complete regression of the lymphoedema and remained well until April 1993 when the lymphoedema recurred. He died while being evaluated for further treatment. Although there is no evidence to suggest that SCD confers any protection from development of neoplasms, the co-existence of SCD with a neoplasm is not common. We consider the occurrence of HE of bone, a rare malignancy, in a HbSC patient worthy of reporting.
PubMed: 10457808
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 005119
- to stream PubMed, to step Curation: 005119
- to stream PubMed, to step Checkpoint: 005119
Links to Exploration step
pubmed:10457808Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignant haemangioendothelioma of bone in a HbSC disease patient--a case report.</title>
<author><name sortKey="Shokunbi, W A" sort="Shokunbi, W A" uniqKey="Shokunbi W" first="W A" last="Shokunbi">W A Shokunbi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, University College Hospital, Ibadan, Nigeria.</nlm:affiliation>
<country xml:lang="fr">Nigeria</country>
<wicri:regionArea>Department of Haematology, University College Hospital, Ibadan</wicri:regionArea>
<wicri:noRegion>Ibadan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Campbell, O B" sort="Campbell, O B" uniqKey="Campbell O" first="O B" last="Campbell">O B Campbell</name>
</author>
<author><name sortKey="Ogunbiyi, J O" sort="Ogunbiyi, J O" uniqKey="Ogunbiyi J" first="J O" last="Ogunbiyi">J O Ogunbiyi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1996">1996</date>
<idno type="RBID">pubmed:10457808</idno>
<idno type="pmid">10457808</idno>
<idno type="wicri:Area/PubMed/Corpus">005119</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005119</idno>
<idno type="wicri:Area/PubMed/Curation">005119</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005119</idno>
<idno type="wicri:Area/PubMed/Checkpoint">005119</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005119</idno>
<idno type="wicri:Area/Ncbi/Merge">000159</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Malignant haemangioendothelioma of bone in a HbSC disease patient--a case report.</title>
<author><name sortKey="Shokunbi, W A" sort="Shokunbi, W A" uniqKey="Shokunbi W" first="W A" last="Shokunbi">W A Shokunbi</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, University College Hospital, Ibadan, Nigeria.</nlm:affiliation>
<country xml:lang="fr">Nigeria</country>
<wicri:regionArea>Department of Haematology, University College Hospital, Ibadan</wicri:regionArea>
<wicri:noRegion>Ibadan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Campbell, O B" sort="Campbell, O B" uniqKey="Campbell O" first="O B" last="Campbell">O B Campbell</name>
</author>
<author><name sortKey="Ogunbiyi, J O" sort="Ogunbiyi, J O" uniqKey="Ogunbiyi J" first="J O" last="Ogunbiyi">J O Ogunbiyi</name>
</author>
</analytic>
<series><title level="j">African journal of medicine and medical sciences</title>
<idno type="ISSN">0309-3913</idno>
<imprint><date when="1996" type="published">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Anemia, Sickle Cell (complications)</term>
<term>Biopsy</term>
<term>Bone Neoplasms (complications)</term>
<term>Bone Neoplasms (drug therapy)</term>
<term>Bone Neoplasms (pathology)</term>
<term>Bone Neoplasms (radiotherapy)</term>
<term>Combined Modality Therapy</term>
<term>Fatal Outcome</term>
<term>Hemangioendothelioma (diagnosis)</term>
<term>Hemangioendothelioma (drug therapy)</term>
<term>Hemangioendothelioma (radiotherapy)</term>
<term>Hemangioendothelioma (secondary)</term>
<term>Humans</term>
<term>Ilium</term>
<term>Leg</term>
<term>Male</term>
<term>Soft Tissue Neoplasms (diagnosis)</term>
<term>Soft Tissue Neoplasms (drug therapy)</term>
<term>Soft Tissue Neoplasms (radiotherapy)</term>
<term>Soft Tissue Neoplasms (secondary)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Association thérapeutique</term>
<term>Biopsie</term>
<term>Drépanocytose ()</term>
<term>Humains</term>
<term>Hémangioendothéliome (diagnostic)</term>
<term>Hémangioendothéliome (radiothérapie)</term>
<term>Hémangioendothéliome (secondaire)</term>
<term>Hémangioendothéliome (traitement médicamenteux)</term>
<term>Ilium</term>
<term>Issue fatale</term>
<term>Jambe</term>
<term>Mâle</term>
<term>Tumeurs des tissus mous (diagnostic)</term>
<term>Tumeurs des tissus mous (radiothérapie)</term>
<term>Tumeurs des tissus mous (secondaire)</term>
<term>Tumeurs des tissus mous (traitement médicamenteux)</term>
<term>Tumeurs osseuses ()</term>
<term>Tumeurs osseuses (anatomopathologie)</term>
<term>Tumeurs osseuses (radiothérapie)</term>
<term>Tumeurs osseuses (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs osseuses</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Anemia, Sickle Cell</term>
<term>Bone Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hemangioendothelioma</term>
<term>Soft Tissue Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hémangioendothéliome</term>
<term>Tumeurs des tissus mous</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term>
<term>Hemangioendothelioma</term>
<term>Soft Tissue Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Bone Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Bone Neoplasms</term>
<term>Hemangioendothelioma</term>
<term>Soft Tissue Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Hémangioendothéliome</term>
<term>Tumeurs des tissus mous</term>
<term>Tumeurs osseuses</term>
</keywords>
<keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Hémangioendothéliome</term>
<term>Tumeurs des tissus mous</term>
</keywords>
<keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Hemangioendothelioma</term>
<term>Soft Tissue Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hémangioendothéliome</term>
<term>Tumeurs des tissus mous</term>
<term>Tumeurs osseuses</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Biopsy</term>
<term>Combined Modality Therapy</term>
<term>Fatal Outcome</term>
<term>Humans</term>
<term>Ilium</term>
<term>Leg</term>
<term>Male</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Association thérapeutique</term>
<term>Biopsie</term>
<term>Drépanocytose</term>
<term>Humains</term>
<term>Ilium</term>
<term>Issue fatale</term>
<term>Jambe</term>
<term>Mâle</term>
<term>Tumeurs osseuses</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report here a 35-year-old man with sickle cell disease (SCD), who presented in 1989 with pain in the (R) hip of 7 years duration and swelling of the (R) calf of 3 months duration. Clinical examination revealed a hard tender mass in the (R) calf. Histology of the (R) calf mass revealed haemangioendothelioma (HE), similar to the histology of the (R) iliac bone mass obtained in another institution previously. He was treated with external radiotherapy with the 1.25 megavoltage beam to antero-posterior fields of the (R) hemipelvis and (R) calf, with good response. Chemotherapy was subsequently administered using 6 cycles of VAC regime. The patient remained in remission for 12 months. In 1991 he had lymphoedema of (R) lower limb and received further radiotherapy and chemotherapy after an isotope bone scan had revealed disease activity in the (R) hemipelvis, (R) femur and (L) upper tibia. He responded again with complete regression of the lymphoedema and remained well until April 1993 when the lymphoedema recurred. He died while being evaluated for further treatment. Although there is no evidence to suggest that SCD confers any protection from development of neoplasms, the co-existence of SCD with a neoplasm is not common. We consider the occurrence of HE of bone, a rare malignancy, in a HbSC patient worthy of reporting.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10457808</PMID>
<DateCreated><Year>1999</Year>
<Month>09</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted><Year>1999</Year>
<Month>09</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2004</Year>
<Month>11</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0309-3913</ISSN>
<JournalIssue CitedMedium="Print"><Volume>25</Volume>
<Issue>3</Issue>
<PubDate><Year>1996</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>African journal of medicine and medical sciences</Title>
<ISOAbbreviation>Afr J Med Med Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Malignant haemangioendothelioma of bone in a HbSC disease patient--a case report.</ArticleTitle>
<Pagination><MedlinePgn>293-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We report here a 35-year-old man with sickle cell disease (SCD), who presented in 1989 with pain in the (R) hip of 7 years duration and swelling of the (R) calf of 3 months duration. Clinical examination revealed a hard tender mass in the (R) calf. Histology of the (R) calf mass revealed haemangioendothelioma (HE), similar to the histology of the (R) iliac bone mass obtained in another institution previously. He was treated with external radiotherapy with the 1.25 megavoltage beam to antero-posterior fields of the (R) hemipelvis and (R) calf, with good response. Chemotherapy was subsequently administered using 6 cycles of VAC regime. The patient remained in remission for 12 months. In 1991 he had lymphoedema of (R) lower limb and received further radiotherapy and chemotherapy after an isotope bone scan had revealed disease activity in the (R) hemipelvis, (R) femur and (L) upper tibia. He responded again with complete regression of the lymphoedema and remained well until April 1993 when the lymphoedema recurred. He died while being evaluated for further treatment. Although there is no evidence to suggest that SCD confers any protection from development of neoplasms, the co-existence of SCD with a neoplasm is not common. We consider the occurrence of HE of bone, a rare malignancy, in a HbSC patient worthy of reporting.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shokunbi</LastName>
<ForeName>W A</ForeName>
<Initials>WA</Initials>
<AffiliationInfo><Affiliation>Department of Haematology, University College Hospital, Ibadan, Nigeria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Campbell</LastName>
<ForeName>O B</ForeName>
<Initials>OB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ogunbiyi</LastName>
<ForeName>J O</ForeName>
<Initials>JO</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Nigeria</Country>
<MedlineTA>Afr J Med Med Sci</MedlineTA>
<NlmUniqueID>7801013</NlmUniqueID>
<ISSNLinking>0309-3913</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000755" MajorTopicYN="N">Anemia, Sickle Cell</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006390" MajorTopicYN="N">Hemangioendothelioma</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
<QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007085" MajorTopicYN="Y">Ilium</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007866" MajorTopicYN="Y">Leg</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012983" MajorTopicYN="N">Soft Tissue Neoplasms</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
<QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year>
<Month>9</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1999</Year>
<Month>8</Month>
<Day>24</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1996</Year>
<Month>9</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10457808</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Nigeria</li>
</country>
</list>
<tree><noCountry><name sortKey="Campbell, O B" sort="Campbell, O B" uniqKey="Campbell O" first="O B" last="Campbell">O B Campbell</name>
<name sortKey="Ogunbiyi, J O" sort="Ogunbiyi, J O" uniqKey="Ogunbiyi J" first="J O" last="Ogunbiyi">J O Ogunbiyi</name>
</noCountry>
<country name="Nigeria"><noRegion><name sortKey="Shokunbi, W A" sort="Shokunbi, W A" uniqKey="Shokunbi W" first="W A" last="Shokunbi">W A Shokunbi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000159 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000159 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:10457808 |texte= Malignant haemangioendothelioma of bone in a HbSC disease patient--a case report. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10457808" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |